Related Experiment Video
Updated: Jan 30, 2026

Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Peter C Hart1, Tatsuyuki Chiyoda1,2, Xiaojing Liu3
1Department of Obstetrics and Gynecology, The University of Chicago, Chicago, Illinois.
Abstract:
The role of phospholipid signaling in ovarian cancer is poorly understood. Sphingosine-1-phosphate (S1P) is a bioactive metabolite of sphingosine that has been associated with tumor progression through enhanced cell proliferation and motility. Similarly, sphingosine kinases (SPHK), which catalyze the formation of S1P and thus regulate the sphingolipid rheostat, have been reported to promote tumor growth in a variety of cancers. The findings reported here show that exogenous S1P or overexpression of SPHK1 increased proliferation, migration, invasion, and stem-like phenotypes in ovarian cancer cell lines. Likewise, overexpression of SPHK1 markedly enhanced tumor growth in a xenograft model of ovarian cancer, which was associated with elevation of key markers of proliferation and stemness. The diabetes drug, metformin, has been shown to have anticancer effects. Here, we found that ovarian cancer patients taking metformin had significantly reduced serum S1P levels, a finding that was recapitulated when ovarian cancer cells were treated with metformin and analyzed by lipidomics. These findings suggested that in cancer the sphingolipid rheostat may be a novel metabolic target of metformin. In support of this, metformin blocked hypoxia-induced SPHK1, which was associated with inhibited nuclear translocation and transcriptional activity of hypoxia-inducible factors (HIF1α and HIF2α). Further, ovarian cancer cells with high SPHK1 were found to be highly sensitive to the cytotoxic effects of metformin, whereas ovarian cancer cells with low SPHK1 were resistant. Together, the findings reported here show that hypoxia-induced SPHK1 expression and downstream S1P signaling promote ovarian cancer progression and that tumors with high expression of SPHK1 or S1P levels might have increased sensitivity to the cytotoxic effects of metformin. IMPLICATIONS: Metformin targets sphingolipid metabolism through inhibiting SPHK1, thereby impeding ovarian cancer cell migration, proliferation, and self-renewal.
Insights
Metformin inhibits sphingosine kinase 1 (SPHK1) and sphingosine-1-phosphate (S1P) signaling, slowing ovarian cancer progression. Tumors with high SPHK1 expression may respond better to metformin treatment.
Area of Science:
- Oncology
- Biochemistry
- Metabolism
Background:
- Phospholipid signaling's role in ovarian cancer is unclear.
- Sphingosine-1-phosphate (S1P) and sphingosine kinases (SPHK) are linked to tumor progression in various cancers.
Purpose of the Study:
- To investigate the role of S1P and SPHK1 in ovarian cancer progression.
- To explore metformin's effect on sphingolipid metabolism in ovarian cancer.
Main Methods:
- Ovarian cancer cell lines were treated with S1P or SPHK1.
- Xenograft models were used to assess tumor growth.
- Lipidomics and Western blotting were employed to analyze molecular changes.
- Ovarian cancer patient data and cell sensitivity to metformin were evaluated.
Main Results:
- Exogenous S1P and SPHK1 overexpression increased ovarian cancer cell proliferation, migration, invasion, and stem-like properties.
- SPHK1 overexpression enhanced tumor growth in vivo, correlating with proliferation and stemness markers.
- Metformin treatment reduced serum S1P levels in patients and in cell cultures.
- Metformin inhibited hypoxia-induced SPHK1, impacting HIF1α and HIF2α activity.
- Ovarian cancer cells with high SPHK1 expression were more sensitive to metformin's cytotoxic effects.
Conclusions:
- Hypoxia-induced SPHK1 and S1P signaling drive ovarian cancer progression.
- Metformin targets sphingolipid metabolism by inhibiting SPHK1.
- Tumors with high SPHK1 or S1P levels may benefit from metformin therapy due to increased sensitivity.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Ovarian Cycle
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

